An international team of neuroscientists, led by Duke-NUS Medical School, have uncovered a mechanism that controls the reactivation of neural stem cells, which are crucial for repairing and ...

In response, multiple Feinberg investigators have sought to identify new mechanisms that contribute to glioblastoma tumor growth, which can help tailor the development of new precision medicine ...

Private prosecutions and alternative dispute resolution mechanisms, such as the National Prosecuting Authority's (NPA) recently published Corporate Alternative Dispute Resolution Policy (the C - ADR ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

Around £2billion was added to the value of GSK after the pharmaceuticals giant agreed a £1.7billion settlement over claims that its heartburn medicine Zantac caused cancer. Shares rose 3.2 per ...

GSK agreed to pay $2.2 billion to settle approximately 80,000 lawsuits in U.S. courts over claims its heartburn drug, Zantac, caused cancer. The settlements account for 93% of all cases and were ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

UK pharmaceutical giant, GSK said it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

However the pharmaceutical giant said it has not admitted any liability by settling the case as the scientific consensus remains that there is no consistent or reliable evidence that ranitidine is ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.